Agnès Buzyn, Minister of Solidarity and Health, announced on April 16, 2019 the list of the ten winners of the first call for projects of the Health Data Hub. The PIMPON Project (Prioritization of Medicinal Interactions by their Clinical PONderation), presented by VIDAL, is one of them, chosen by a jury of experts from 189 submissions.
Tired of misinformation in health care? Lost in contradictory information on the treatment or prevention of diseases? EurekaSante.fr, VIDAL's public website, is celebrating its 10th anniversary. Ten years of health information based on the recommendations of public health authorities and learned societies. In case of doubt, EurekaSante.fr remains THE source of information and easy to understand on all aspects of health.
VIDAL's mission has always been to inform and support healthcare professionals with a view to continuously improving therapeutic management.
Today, as part of their professional training, doctors are increasingly turning to the Internet and online digital solutions to update their knowledge. Saving time and a real desire to remain an active participant in their training are the main reasons for their choice.
In order to understand physicians' expectations in terms of medical training, VIDAL conducted its own survey in March 2018 among 393 practitioners (general practitioners and hospitalists).
The French National Olympic and Sports Committee (CNOSF), launched this Monday, December 3, 2018, in partnership with VIDAL, the digital version of Médicosport-santé. The Médicosport-santé is a dictionary with a medical purpose of sports disciplines that lists the physical, physiological and mental characteristics of each sport discipline as well as the conditions of practice in the context of sport-health (primary, secondary and tertiary prevention). To date, 45 sports federations have joined the system.
VIDAL Group, a drug information specialist, announces a draft agreement providing for the acquisition of the entire group by the Japanese company M3 for approximately €100 million. This draft agreement is expected to be finalized by the end of 2016. M3 is a leader in the medical information and new technologies sector in Japan, the US and worldwide. A leader in the field of healthcare product databases, VIDAL Group has led a complete transition to digital in recent years to become a key player in medical information in France and Europe.